TRAT1

Across TCGA pan-cancer cohorts, TRAT1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRAT1 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher TRAT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAT1 expression acts as an unfavorable survival marker.

THYM, LUAD, and LIHC are the cancer types where TRAT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	OS	Median	III,IV	0.053	0.661	<.001	16	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	OS	Median	III,IV	0.382	0.734	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRAT1–THYM (OS)

Open the THYM breakdown →